cabazitaxel,lutetium lu 177 vipivotide tetraxetan
novartis,sanofi,emcure
['therap ']
another reminder: the therap update of cabazi (20mg) vs lu-psma: no os difference.
lutetium is an option but not always better (suv mean is predictive of outcomes).
#esmo2022 
Enjoying oncology, without meaning to sound too cynical